TD Private Client Wealth LLC Sells 1,488 Shares of Danaher Co. (NYSE:DHR)

TD Private Client Wealth LLC decreased its position in Danaher Co. (NYSE:DHR) by 8.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 16,458 shares of the conglomerate’s stock after selling 1,488 shares during the quarter. TD Private Client Wealth LLC’s holdings in Danaher were worth $3,778,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. FMR LLC grew its holdings in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Danaher by 5.4% during the 4th quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate’s stock worth $1,971,609,000 after acquiring an additional 441,012 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Danaher by 3.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after acquiring an additional 148,251 shares during the last quarter. Fisher Asset Management LLC grew its holdings in Danaher by 0.6% during the 4th quarter. Fisher Asset Management LLC now owns 4,578,945 shares of the conglomerate’s stock worth $1,051,097,000 after acquiring an additional 26,305 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Danaher by 3.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,066,755 shares of the conglomerate’s stock worth $933,524,000 after acquiring an additional 135,047 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of NYSE:DHR opened at $211.63 on Friday. The company has a market capitalization of $151.26 billion, a price-to-earnings ratio of 40.08, a P/E/G ratio of 2.66 and a beta of 0.82. The firm’s 50 day simple moving average is $217.46 and its 200 day simple moving average is $238.86. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the company posted $2.09 EPS. As a group, sell-side analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. This is an increase from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a yield of 0.60%. The ex-dividend date of this dividend is Friday, March 28th. Danaher’s dividend payout ratio (DPR) is 24.24%.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 10.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on DHR. Barclays decreased their price objective on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Guggenheim began coverage on shares of Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective on the stock. Scotiabank began coverage on shares of Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective on the stock. Citigroup cut their target price on shares of Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $277.00 target price (down from $299.00) on shares of Danaher in a research report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $278.24.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.